Arrowhead Pharmaceuticals Inc.
ARWR
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.2B
Close$
$-3.88
106.7% downside
Current Fair Value
106.7% downsideOvervalued by 106.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.20 Billion |
|---|---|
| Enterprise Value | $9.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.3 |
| Outstanding Shares | 143,378,000 |
Return
| Return on Equity | -68.73% |
|---|---|
| Return on Assets | -15.15% |
| Return on Invested Capital | -10.77% |
Valuation & Multiples
| P/E Ratio | -25.9 |
|---|---|
| PEG | -238.41 |
| Price to Sales | 14.51 |
| Price to Book Ratio | 19.34 |
| Enterprise Value to Revenue | 13.59 |
| Enterprise Value to EBIT | -46.2 |
| Enterprise Value to Net Income | -29 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$47.89 M
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-1.52
Average shareholder expectationRevenue Estimate
$61.18 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 43.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.69%▼ 83.18% |
|---|---|
| Total Invested | $64.98M▼ 99.34% |
| Investors Holding | 36▼ 487.00% |
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
711 employees
CEO: Christopher Anzalone Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interf...